$19.120
-0.572 (-2.99%)收盤時
ACAD 資訊
ACAD 事件
RBC Analyst Says Acadia Pharmaceuticals and Zydus Reach Settlement
RBC Capital analyst Brian Abrahams says the firm's checks found that Acadia Pharmaceuticals and generic drugmaker Zydus filed a joint stipulation to dismiss all claims and counterclaims in the patent litigation related to Nuplazid a month befor a trial scheduled for November 2. A dismissal of this nature, filed jointly one month before trial and after over a year of litigation, is consistent with a settlement of entry date for a generic, says the analyst, who keeps an Outperform rating and $37 price target on Acadia shares.
Acadia Pharmaceuticals Shares Down 10.2% to $22.83
Acadia Pharmaceuticals is down -10.2%, or -$2.60 to $22.83.
Stock Futures Decline as Treasury Yields Rise
Stock futures have slumped Thursday as a sharp rise in Treasury yields and renewed oil price gains weighed on equities, more than offsetting renewed AI optimism following Meta'sMuse product rollout event.In pre-market trading, S&P 500 futures declined 0.5%, Nasdaq 100 futures fell 0.95% and Dow futures lost 0.26%.Check out this morning's top movers from around Wall Street, compiled by The Fly.HIGHER -Knife Riverup 5% following Starboard Value announcing a position and plans to push the company's management to improve its margins or explore a saleEverpureup 6% after the company forecast revenue for 2028 that exceeded estimatesDolby Labsup 4% after the company announced the expansion of Dolby experiences within the Meta ecosystem of devices and platformsUP AFTER EARNINGS -H.B. Fullerup 1%BlackBerryup 1%DOWN AFTER EARNINGS -Stitch Fixdown 17%Dardendown 4%TD Synnexdown 10%LOWER -MGM Resortsdown 10% after Barry Diller's Peopledropped plans to acquire the rest of the casino company it does not already ownDropboxdown 5% after Citi downgraded the stock to SellEtsydown 2% after Arete downgraded the stock to Neutral from BuyViking Therapeuticsdown 12% after offering $200M in common shares and another $200M in convertible notes to help fund clinical developmentAcadia Pharmaceuticalsdown 5% after saying its Phase 2 portion of RADIANT trial "narrowly missed" its primary endpoint
Acadia Pharmaceuticals Down 6% at $23.93 After Update on Phase 2 RADIANT Trial
Acadia Pharmaceuticals down 6% at $23.93 after update on Phase 2 RADIANT trial
Acadia Pharmaceuticals Announces Phase 3 Results for Alzheimer's Drug
Acadia Pharmaceuticals announced Phase 3 enabling topline results from the Phase 2 portion of the ongoing RADIANT clinical trial program evaluating remlifanserin for the treatment of hallucinations and delusions associated with Alzheimer's disease psychosis. For the primary endpoint of change from baseline in the Scale for the Assessment of Positive Symptoms-Hallucinations and Delusions subscales, once daily 60 mg remlifanserin demonstrated a change of -12.6 versus a -10.4 change for placebo at week 6, yielding a standardized effect size of 0.26. For the key secondary endpoint, Clinical Global Impression - Severity the 60 mg dose achieved a change from baseline of -1.3 versus a change of -0.9 for placebo at week 6, yielding a standardized effect size of 0.37. On both efficacy measures, the difference in the 60 mg dose versus placebo increased through the 6-week treatment period. The 30 mg dose showed minimal improvement across endpoints compared to placebo. All analyses were performed in the pre-specified modified full analysis set population. In this study, across both doses, remlifanserin demonstrated a favorable safety profile, with rates of adverse events, serious adverse events, and discontinuations due to adverse events, similar to placebo. There was no signal of QT prolongation versus placebo. This dataset suggests no negative impact on motor symptoms or cognition. Additionally, there were no deaths in the remlifanserin treatment arms. Given these data, Acadia plans to continue enrolling its two ongoing Phase 3 studies evaluating remlifanserin in ADP while implementing amendments to the Phase 3 program, including removing the 30 mg dosage arm. Additionally, remlifanserin is currently being investigated in an additional Phase 2 study to evaluate its efficacy, safety and tolerability for the treatment of Lewy body dementia psychosis.
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。